Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TissueGene-C
- Development stage
- Phase 3
- Lead developer
- Kolon TissueGene
- Modality
- Cell Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intraarticular
01
Overview
TissueGene-C (TG-C) is a first-in-class cell and gene therapy developed for the treatment of osteoarthritis, particularly knee osteoarthritis. It consists of a mixture of human allogeneic chondrocytes and irradiated cells engineered to overexpress transforming growth factor-β1 (TGF-β1). Administered as a single intra-articular injection, TG-C aims to relieve pain, improve joint function, and regenerate cartilage structure by creating an anti-inflammatory microenvironment dominated by M2 macrophages. Clinical trials have demonstrated its potential to provide long-term pain relief and functional improvement in patients with osteoarthritis. The therapy is being positioned as a disease-modifying osteoarthritis drug (DMOAD), potentially making it the first such approved therapy for this indication[3][4][5].
- Brand names
- InvossaInvossa-K InjInvossa K Injection
- Other names
- TG-C LD
02
Targets
TGFBR1EP2/EP4 (Prostaglandin E receptor 2 and Prostaglandin E receptor 4)
Beyond the preview
Go deeper on TissueGene-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TissueGene-C.